83_FR_12246 83 FR 12192 - Nectar Brand LLC; Analysis To Aid Public Comment

83 FR 12192 - Nectar Brand LLC; Analysis To Aid Public Comment

FEDERAL TRADE COMMISSION

Federal Register Volume 83, Issue 54 (March 20, 2018)

Page Range12192-12193
FR Document2018-05613

The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices. The attached Analysis to Aid Public Comment describes both the allegations in the complaint and the terms of the consent order-- embodied in the consent agreement--that would settle these allegations.

Federal Register, Volume 83 Issue 54 (Tuesday, March 20, 2018)
[Federal Register Volume 83, Number 54 (Tuesday, March 20, 2018)]
[Notices]
[Pages 12192-12193]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-05613]



[[Page 12192]]

=======================================================================
-----------------------------------------------------------------------

FEDERAL TRADE COMMISSION

[File No. 182 3038]


Nectar Brand LLC; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement.

-----------------------------------------------------------------------

SUMMARY: The consent agreement in this matter settles alleged 
violations of federal law prohibiting unfair or deceptive acts or 
practices. The attached Analysis to Aid Public Comment describes both 
the allegations in the complaint and the terms of the consent order--
embodied in the consent agreement--that would settle these allegations.

DATES: Comments must be received on or before April 12, 2018.

ADDRESSES: Interested parties may file a comment online or on paper, by 
following the instructions in the Request for Comment part of the 
SUPPLEMENTARY INFORMATION section below. Write: ``In the Matter of 
Nectar Brand LLC, a limited liability company, also doing business as 
Nectar Sleep; DreamCloud, LLC; and DreamCloud Brand LLC'' on your 
comment, and file your comment online at https://ftcpublic.commentworks.com/ftc/nectarbrandconsent by following the 
instructions on the web-based form. If you prefer to file your comment 
on paper, write ``In the Matter of Nectar Brand LLC, a limited 
liability company, also doing business as Nectar Sleep; DreamCloud, 
LLC; and DreamCloud Brand LLC'' on your comment and on the envelope, 
and mail your comment to the following address: Federal Trade 
Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite 
CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the 
following address: Federal Trade Commission, Office of the Secretary, 
Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex 
D), Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: Julia Solomon Ensor (202-326-2377) and 
Crystal Ostrum (202-326-3405), Bureau of Consumer Protection, 600 
Pennsylvania Avenue NW, Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal 
Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, 
notice is hereby given that the above-captioned consent agreement 
containing a consent order to cease and desist, having been filed with 
and accepted, subject to final approval, by the Commission, has been 
placed on the public record for a period of thirty (30) days. The 
following Analysis to Aid Public Comment describes the terms of the 
consent agreement, and the allegations in the complaint. An electronic 
copy of the full text of the consent agreement package can be obtained 
from the FTC Home Page (for March 13, 2018), on the World Wide Web, at 
https://www.ftc.gov/news-events/commission-actions.
    You can file a comment online or on paper. For the Commission to 
consider your comment, we must receive it on or before April 12, 2018. 
Write ``In the Matter of Nectar Brand LLC, a limited liability company, 
also doing business as Nectar Sleep; DreamCloud, LLC; and DreamCloud 
Brand LLC'' on your comment. Your comment--including your name and your 
state--will be placed on the public record of this proceeding, 
including, to the extent practicable, on the public Commission website, 
at https://www.ftc.gov/policy/public-comments.
    Postal mail addressed to the Commission is subject to delay due to 
heightened security screening. As a result, we encourage you to submit 
your comments online. To make sure that the Commission considers your 
online comment, you must file it at https://ftcpublic.commentworks.com/ftc/nectarbrandconsent by following the instructions on the web-based 
form. If this Notice appears at http://www.regulations.gov/#!home, you 
also may file a comment through that website.
    If you prefer to file your comment on paper, write ``In the Matter 
of Nectar Brand LLC, a limited liability company, also doing business 
as Nectar Sleep; DreamCloud, LLC; and DreamCloud Brand LLC'' on your 
comment and on the envelope, and mail your comment to the following 
address: Federal Trade Commission, Office of the Secretary, 600 
Pennsylvania Avenue NW, Suite CC-5610 (Annex D), Washington, DC 20580, 
or deliver your comment to the following address: Federal Trade 
Commission, Office of the Secretary, Constitution Center, 400 7th 
Street SW, 5th Floor, Suite 5610 (Annex D), Washington, DC 20024. If 
possible, submit your paper comment to the Commission by courier or 
overnight service.
    Because your comment will be placed on the publicly accessible FTC 
website at https://www.ftc.gov, you are solely responsible for making 
sure that your comment does not include any sensitive or confidential 
information. In particular, your comment should not include any 
sensitive personal information, such as your or anyone else's Social 
Security number; date of birth; driver's license number or other state 
identification number, or foreign country equivalent; passport number; 
financial account number; or credit or debit card number. You are also 
solely responsible for making sure that your comment does not include 
any sensitive health information, such as medical records or other 
individually identifiable health information. In addition, your comment 
should not include any ``trade secret or any commercial or financial 
information which . . . is privileged or confidential''--as provided by 
Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 
16 CFR 4.10(a)(2)--including in particular competitively sensitive 
information such as costs, sales statistics, inventories, formulas, 
patterns, devices, manufacturing processes, or customer names.
    Comments containing material for which confidential treatment is 
requested must be filed in paper form, must be clearly labeled 
``Confidential,'' and must comply with FTC Rule 4.9(c). In particular, 
the written request for confidential treatment that accompanies the 
comment must include the factual and legal basis for the request, and 
must identify the specific portions of the comment to be withheld from 
the public record. See FTC Rule 4.9(c). Your comment will be kept 
confidential only if the General Counsel grants your request in 
accordance with the law and the public interest. Once your comment has 
been posted on the public FTC website--as legally required by FTC Rule 
4.9(b)--we cannot redact or remove your comment from the FTC website, 
unless you submit a confidentiality request that meets the requirements 
for such treatment under FTC Rule 4.9(c), and the General Counsel 
grants that request.
    Visit the FTC website at http://www.ftc.gov to read this Notice and 
the news release describing it. The FTC Act and other laws that the 
Commission administers permit the collection of public comments to 
consider and use in this proceeding, as appropriate. The Commission 
will consider all timely and responsive public comments that it 
receives on or before April 12, 2018. For information on the 
Commission's privacy policy, including routine uses permitted by the 
Privacy Act, see https://www.ftc.gov/site-information/privacy-policy.

Analysis of Proposed Consent Order To Aid Public Comment

    The Federal Trade Commission (``FTC'' or ``Commission'') has 
accepted, subject to final approval, an agreement

[[Page 12193]]

containing a consent order from Nectar Brand LLC, also d/b/a Nectar 
Sleep; Dreamcloud, LLC; and Dreamcloud Brand LLC (``respondent'').
    The proposed consent order has been placed on the public record for 
thirty (30) days for receipt of comments by interested persons. 
Comments received during this period will become part of the public 
record. After thirty (30) days, the Commission will again review the 
agreement and the comments received, and will decide whether it should 
withdraw from the agreement or make final the agreement's proposed 
order.
    This matter involves respondent's marketing, sale, and distribution 
of mattresses with claims that the products are assembled in the United 
States.
    According to the FTC's complaint, respondent represented that its 
products are ``assembled in the USA.'' In fact, the respondent's 
mattresses are wholly imported. Therefore, this representation was 
false or misleading. Based on the foregoing, the complaint alleges that 
respondent engaged in deceptive acts or practices in violation of 
Section 5(a) of the FTC Act.
    The proposed consent order contains provisions designed to prevent 
respondent from engaging in similar acts and practices in the future. 
Consistent with the FTC's Enforcement Policy Statement on U.S. Origin 
Claims, Part I prohibits respondent from making U.S.-origin claims for 
their products unless either: (1) The final assembly or processing of 
the product occurs in the United States, all significant processing 
that goes into the product occurs in the United States, and all or 
virtually all ingredients or components of the product are made and 
sourced in the United States; (2) a clear and conspicuous qualification 
appears immediately adjacent to the representation that accurately 
conveys the extent to which the product contains foreign parts, 
ingredients or components, and/or processing; or (3) for a claim that a 
product is assembled in the United States, the product is last 
substantially transformed in the United States, the product's principal 
assembly takes place in the United States, and United States assembly 
operations are substantial.
    Part II prohibits respondent from making any country-of-origin 
claim about a product or service unless the claim is true, not 
misleading, and respondent has a reasonable basis substantiating the 
representation.
    Parts III through V are reporting and compliance provisions. Part 
III requires the filing of compliance reports within one year after the 
order becomes final and within 14 days of any change that would affect 
compliance with the order. Part IV requires respondent to maintain 
certain records, including records necessary to demonstrate compliance 
with the order. Part V requires respondent to submit additional 
compliance reports when requested by the Commission and to permit the 
Commission or its representatives to interview respondent's personnel.
    Finally, Part VI is a ``sunset'' provision, terminating the order 
after twenty (20) years, with certain exceptions.
    The purpose of this analysis is to aid public comment on the 
proposed order. It is not intended to constitute an official 
interpretation of the proposed order or to modify its terms in any way.

    By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018-05613 Filed 3-19-18; 8:45 am]
BILLING CODE 6750-01-P



                                               12192                         Federal Register / Vol. 83, No. 54 / Tuesday, March 20, 2018 / Notices

                                               FEDERAL TRADE COMMISSION                                of thirty (30) days. The following                    else’s Social Security number; date of
                                                                                                       Analysis to Aid Public Comment                        birth; driver’s license number or other
                                               [File No. 182 3038]
                                                                                                       describes the terms of the consent                    state identification number, or foreign
                                               Nectar Brand LLC; Analysis To Aid                       agreement, and the allegations in the                 country equivalent; passport number;
                                               Public Comment                                          complaint. An electronic copy of the                  financial account number; or credit or
                                                                                                       full text of the consent agreement                    debit card number. You are also solely
                                               AGENCY:    Federal Trade Commission.                    package can be obtained from the FTC                  responsible for making sure that your
                                               ACTION:   Proposed consent agreement.                   Home Page (for March 13, 2018), on the                comment does not include any sensitive
                                                                                                       World Wide Web, at https://                           health information, such as medical
                                               SUMMARY:   The consent agreement in this                www.ftc.gov/news-events/commission-                   records or other individually
                                               matter settles alleged violations of                    actions.                                              identifiable health information. In
                                               federal law prohibiting unfair or                          You can file a comment online or on                addition, your comment should not
                                               deceptive acts or practices. The attached               paper. For the Commission to consider                 include any ‘‘trade secret or any
                                               Analysis to Aid Public Comment                          your comment, we must receive it on or                commercial or financial information
                                               describes both the allegations in the                   before April 12, 2018. Write ‘‘In the                 which . . . is privileged or
                                               complaint and the terms of the consent                  Matter of Nectar Brand LLC, a limited                 confidential’’—as provided by Section
                                               order—embodied in the consent                           liability company, also doing business                6(f) of the FTC Act, 15 U.S.C. 46(f), and
                                               agreement—that would settle these                       as Nectar Sleep; DreamCloud, LLC; and                 FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
                                               allegations.                                            DreamCloud Brand LLC’’ on your                        including in particular competitively
                                               DATES: Comments must be received on                     comment. Your comment—including                       sensitive information such as costs,
                                               or before April 12, 2018.                               your name and your state—will be                      sales statistics, inventories, formulas,
                                               ADDRESSES: Interested parties may file a                placed on the public record of this                   patterns, devices, manufacturing
                                               comment online or on paper, by                          proceeding, including, to the extent                  processes, or customer names.
                                               following the instructions in the                       practicable, on the public Commission                    Comments containing material for
                                               Request for Comment part of the                         website, at https://www.ftc.gov/policy/               which confidential treatment is
                                               SUPPLEMENTARY INFORMATION section                       public-comments.                                      requested must be filed in paper form,
                                               below. Write: ‘‘In the Matter of Nectar                    Postal mail addressed to the                       must be clearly labeled ‘‘Confidential,’’
                                               Brand LLC, a limited liability company,                 Commission is subject to delay due to                 and must comply with FTC Rule 4.9(c).
                                               also doing business as Nectar Sleep;                    heightened security screening. As a                   In particular, the written request for
                                               DreamCloud, LLC; and DreamCloud                         result, we encourage you to submit your               confidential treatment that accompanies
                                               Brand LLC’’ on your comment, and file                   comments online. To make sure that the                the comment must include the factual
                                               your comment online at https://                         Commission considers your online                      and legal basis for the request, and must
                                               ftcpublic.commentworks.com/ftc/                         comment, you must file it at https://                 identify the specific portions of the
                                               nectarbrandconsent by following the                     ftcpublic.commentworks.com/ftc/                       comment to be withheld from the public
                                               instructions on the web-based form. If                  nectarbrandconsent by following the                   record. See FTC Rule 4.9(c). Your
                                                                                                       instructions on the web-based form. If                comment will be kept confidential only
                                               you prefer to file your comment on
                                                                                                       this Notice appears at http://                        if the General Counsel grants your
                                               paper, write ‘‘In the Matter of Nectar
                                                                                                       www.regulations.gov/#!home, you also                  request in accordance with the law and
                                               Brand LLC, a limited liability company,
                                                                                                       may file a comment through that                       the public interest. Once your comment
                                               also doing business as Nectar Sleep;
                                                                                                       website.                                              has been posted on the public FTC
                                               DreamCloud, LLC; and DreamCloud                            If you prefer to file your comment on
                                               Brand LLC’’ on your comment and on                                                                            website—as legally required by FTC
                                                                                                       paper, write ‘‘In the Matter of Nectar                Rule 4.9(b)—we cannot redact or
                                               the envelope, and mail your comment to                  Brand LLC, a limited liability company,               remove your comment from the FTC
                                               the following address: Federal Trade                    also doing business as Nectar Sleep;                  website, unless you submit a
                                               Commission, Office of the Secretary,                    DreamCloud, LLC; and DreamCloud                       confidentiality request that meets the
                                               600 Pennsylvania Avenue NW, Suite                       Brand LLC’’ on your comment and on                    requirements for such treatment under
                                               CC–5610 (Annex D), Washington, DC                       the envelope, and mail your comment to                FTC Rule 4.9(c), and the General
                                               20580, or deliver your comment to the                   the following address: Federal Trade                  Counsel grants that request.
                                               following address: Federal Trade                        Commission, Office of the Secretary,                     Visit the FTC website at http://
                                               Commission, Office of the Secretary,                    600 Pennsylvania Avenue NW, Suite                     www.ftc.gov to read this Notice and the
                                               Constitution Center, 400 7th Street SW,                 CC–5610 (Annex D), Washington, DC                     news release describing it. The FTC Act
                                               5th Floor, Suite 5610 (Annex D),                        20580, or deliver your comment to the                 and other laws that the Commission
                                               Washington, DC 20024.                                   following address: Federal Trade                      administers permit the collection of
                                               FOR FURTHER INFORMATION CONTACT: Julia                  Commission, Office of the Secretary,                  public comments to consider and use in
                                               Solomon Ensor (202–326–2377) and                        Constitution Center, 400 7th Street SW,               this proceeding, as appropriate. The
                                               Crystal Ostrum (202–326–3405), Bureau                   5th Floor, Suite 5610 (Annex D),                      Commission will consider all timely
                                               of Consumer Protection, 600                             Washington, DC 20024. If possible,                    and responsive public comments that it
                                               Pennsylvania Avenue NW, Washington,                     submit your paper comment to the                      receives on or before April 12, 2018. For
                                               DC 20580.                                               Commission by courier or overnight                    information on the Commission’s
                                               SUPPLEMENTARY INFORMATION: Pursuant                     service.                                              privacy policy, including routine uses
                                               to Section 6(f) of the Federal Trade                       Because your comment will be placed                permitted by the Privacy Act, see
                                               Commission Act, 15 U.S.C. 46(f), and                    on the publicly accessible FTC website                https://www.ftc.gov/site-information/
daltland on DSKBBV9HB2PROD with NOTICES




                                               FTC Rule 2.34, 16 CFR 2.34, notice is                   at https://www.ftc.gov, you are solely                privacy-policy.
                                               hereby given that the above-captioned                   responsible for making sure that your
                                               consent agreement containing a consent                  comment does not include any sensitive                Analysis of Proposed Consent Order To
                                               order to cease and desist, having been                  or confidential information. In                       Aid Public Comment
                                               filed with and accepted, subject to final               particular, your comment should not                      The Federal Trade Commission
                                               approval, by the Commission, has been                   include any sensitive personal                        (‘‘FTC’’ or ‘‘Commission’’) has accepted,
                                               placed on the public record for a period                information, such as your or anyone                   subject to final approval, an agreement


                                          VerDate Sep<11>2014   19:08 Mar 19, 2018   Jkt 244001   PO 00000   Frm 00046   Fmt 4703   Sfmt 4703   E:\FR\FM\20MRN1.SGM   20MRN1


                                                                             Federal Register / Vol. 83, No. 54 / Tuesday, March 20, 2018 / Notices                                                  12193

                                               containing a consent order from Nectar                  would affect compliance with the order.               Officer, Center for Global Health, CDC,
                                               Brand LLC, also d/b/a Nectar Sleep;                     Part IV requires respondent to maintain               1600 Clifton Drive, Atlanta, GA 30331,
                                               Dreamcloud, LLC; and Dreamcloud                         certain records, including records                    (404) 639–4796; HShoob@cdc.gov.
                                               Brand LLC (‘‘respondent’’).                             necessary to demonstrate compliance                     The Director, Management Analysis
                                                  The proposed consent order has been                  with the order. Part V requires                       and Services Office, has been delegated
                                               placed on the public record for thirty                  respondent to submit additional                       the authority to sign Federal Register
                                               (30) days for receipt of comments by                    compliance reports when requested by                  notices pertaining to announcements of
                                               interested persons. Comments received                   the Commission and to permit the                      meetings and other committee
                                               during this period will become part of                  Commission or its representatives to                  management activities, for both the
                                               the public record. After thirty (30) days,              interview respondent’s personnel.                     Centers for Disease Control and
                                               the Commission will again review the                       Finally, Part VI is a ‘‘sunset’’                   Prevention and the Agency for Toxic
                                               agreement and the comments received,                    provision, terminating the order after                Substances and Disease Registry.
                                               and will decide whether it should                       twenty (20) years, with certain
                                               withdraw from the agreement or make                                                                           Elaine L. Baker,
                                                                                                       exceptions.
                                               final the agreement’s proposed order.                      The purpose of this analysis is to aid             Director, Management Analysis and Services
                                                  This matter involves respondent’s                    public comment on the proposed order.                 Office, Centers for Disease Control and
                                               marketing, sale, and distribution of                                                                          Prevention.
                                                                                                       It is not intended to constitute an
                                               mattresses with claims that the products                                                                      [FR Doc. 2018–05577 Filed 3–19–18; 8:45 am]
                                                                                                       official interpretation of the proposed
                                               are assembled in the United States.                     order or to modify its terms in any way.              BILLING CODE 4163–18–P
                                                  According to the FTC’s complaint,
                                                                                                         By direction of the Commission.
                                               respondent represented that its products
                                               are ‘‘assembled in the USA.’’ In fact, the              Donald S. Clark,                                      DEPARTMENT OF HEALTH AND
                                               respondent’s mattresses are wholly                      Secretary.                                            HUMAN SERVICES
                                               imported. Therefore, this representation                [FR Doc. 2018–05613 Filed 3–19–18; 8:45 am]
                                               was false or misleading. Based on the                   BILLING CODE 6750–01–P
                                                                                                                                                             Centers for Disease Control and
                                               foregoing, the complaint alleges that                                                                         Prevention
                                               respondent engaged in deceptive acts or
                                                                                                                                                             Notice of Closed Meeting
                                               practices in violation of Section 5(a) of               DEPARTMENT OF HEALTH AND
                                               the FTC Act.                                            HUMAN SERVICES                                          Pursuant to section 10(d) of the
                                                  The proposed consent order contains                                                                        Federal Advisory Committee Act, as
                                               provisions designed to prevent                          Centers for Disease Control and                       amended, notice is hereby given of the
                                               respondent from engaging in similar                     Prevention                                            following meeting.
                                               acts and practices in the future.                                                                               The meeting will be closed to the
                                               Consistent with the FTC’s Enforcement                   Notice of Closed Meeting                              public in accordance with the
                                               Policy Statement on U.S. Origin Claims,                   Pursuant to section 10(d) of the                    provisions set forth in sections
                                               Part I prohibits respondent from making                 Federal Advisory Committee Act, as                    552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
                                               U.S.-origin claims for their products                   amended, notice is hereby given of the                as amended, and the Determination of
                                               unless either: (1) The final assembly or                following meeting.                                    the Director, Management Analysis and
                                               processing of the product occurs in the                   The meeting will be closed to the                   Services Office, CDC, pursuant to Public
                                               United States, all significant processing               public in accordance with the                         Law 92–463. The grant applications and
                                               that goes into the product occurs in the                provisions set forth in sections                      the discussions could disclose
                                               United States, and all or virtually all                 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,            confidential trade secrets or commercial
                                               ingredients or components of the                        as amended, and the Determination of                  property such as patentable material,
                                               product are made and sourced in the                     the Director, Management Analysis and                 and personal information concerning
                                               United States; (2) a clear and                          Services Office, CDC, pursuant to Public              individuals associated with the grant
                                               conspicuous qualification appears                       Law 92–463. The grant applications and                applications, the disclosure of which
                                               immediately adjacent to the                             the discussions could disclose                        would constitute a clearly unwarranted
                                               representation that accurately conveys                  confidential trade secrets or commercial              invasion of personal privacy.
                                               the extent to which the product contains                property such as patentable material,                   Name of Committee: Disease,
                                               foreign parts, ingredients or                           and personal information concerning                   Disability, and Injury Prevention and
                                               components, and/or processing; or (3)                   individuals associated with the grant                 Control Special Emphasis Panel (SEP)—
                                               for a claim that a product is assembled                 applications, the disclosure of which                 GH14–002, Addressing Emerging
                                               in the United States, the product is last               would constitute a clearly unwarranted                Infectious Diseases in Bangladesh;
                                               substantially transformed in the United                 invasion of personal privacy.                         GH16–003, Conducting Public Health
                                               States, the product’s principal assembly                  Name of Committee: Disease,                         Research in Thailand: Technical
                                               takes place in the United States, and                   Disability, and Injury Prevention and                 collaboration with the Ministry of
                                               United States assembly operations are                   Control Special Emphasis Panel (SEP)—                 Public Health in the Kingdom of
                                               substantial.                                            GH18–004, Advancing Public Health in                  Thailand (MOPH); GH16–006,
                                                  Part II prohibits respondent from                    Central America (Belize, Costa Rica,                  Conducting Public Health Research in
                                               making any country-of-origin claim                      Dominican Republic, El Salvador,                      Kenya; GH17–005, Conducting Public
                                               about a product or service unless the                   Guatemala, Honduras, Nicaragua,                       Health Research in China.
                                               claim is true, not misleading, and                      Panama).                                                Date: April 10, 2018.
daltland on DSKBBV9HB2PROD with NOTICES




                                               respondent has a reasonable basis                         Date: April 17, 2018.                                 Time: 9:00 a.m.–2:00 p.m., EDT.
                                               substantiating the representation.                        Time: 9:00 a.m.–2:00 p.m., EDT.                       Place: Teleconference.
                                                  Parts III through V are reporting and                  Place: Teleconference.                                Agenda: To review and evaluate grant
                                               compliance provisions. Part III requires                  Agenda: To review and evaluate grant                applications.
                                               the filing of compliance reports within                 applications.                                           For Further Information Contact:
                                               one year after the order becomes final                    For Further Information Contact:                    Hylan Shoob, Ph.D., Scientific Review
                                               and within 14 days of any change that                   Hylan Shoob, Ph.D., Scientific Review                 Officer, Center for Global Health, CDC,


                                          VerDate Sep<11>2014   19:08 Mar 19, 2018   Jkt 244001   PO 00000   Frm 00047   Fmt 4703   Sfmt 4703   E:\FR\FM\20MRN1.SGM   20MRN1



Document Created: 2018-03-20 01:10:35
Document Modified: 2018-03-20 01:10:35
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionProposed consent agreement.
DatesComments must be received on or before April 12, 2018.
ContactJulia Solomon Ensor (202-326-2377) and Crystal Ostrum (202-326-3405), Bureau of Consumer Protection, 600 Pennsylvania Avenue NW, Washington, DC 20580.
FR Citation83 FR 12192 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR